(Q50141101)

English

Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.

scientific article published in December 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

0 references

Mycobacterium avium avium

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

author name string

Sendi PP

1

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

Meier G

3

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

Pfluger D

4

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

Gafni A

5

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

Opravil M

6

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

Battegay M

7

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

Bucher HC

8

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

language of work or name

0 references

publication date

1 December 1999

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

number of pages

7

1 reference

based on heuristic

inferred from page(s)

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

44

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

6

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

811-817

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

Mycobacterium avium complex infection in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

The cost-effectiveness of preventing AIDS-related opportunistic infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Impact of 1993 revision of adult/adolescent AIDS surveillance case-definition for Europe. National Coordinators for AIDS Surveillance in 38 European countries

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: increasing incidence, unchanged prognosis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Pre-AIDS mortality in HIV-infected individuals in England, Wales and Northern Ireland, 1982-1996.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Gains in life expectancy from medical interventions--standardizing data on outcomes

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Discounting in the economic evaluation of health care interventions

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.6.811

21 January 2018

Identifiers

10.1093/JAC/44.6.811

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 February 2018

http://europepmc.org/abstract/MED/10590283

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50141101&oldid=1796628236"